Alkermes plc is an Ireland‑domiciled biopharmaceutical company focused on neuroscience, researching, developing, and manufacturing medicines for serious mental health and addiction disorders. Headquartered in Dublin with substantial U.S. operations, the company integrates drug discovery with formulation science and commercial-scale production.
Alkermes’ portfolio and pipeline emphasize long‑acting injectable and oral small‑molecule therapies that leverage polymer‑based and other controlled‑release technologies. Its commercial products include Vivitrol (extended‑release naltrexone) for alcohol and opioid dependence; Aristada and Aristada Initio (aripiprazole lauroxil) long‑acting injectables for schizophrenia; and Lybalvi (olanzapine and samidorphan) for schizophrenia and bipolar I disorder. The company maintains commercial manufacturing in the United States and supports products with process development, quality, and regulatory capabilities, alongside revenues from collaborations and royalties.
None yet. When a new project in the record names Alkermes as owner, partner or investor, it shows here.
The $92.5M sale includes a subcontracting period until 2025. Alkermes aims for operational efficiency, while Novo Nordisk gains manufacturing capacity and 400 skilled employees.
